Dr. Boarhead’s Summary of Global Updates on the 2019 Novel Coronavirus: 7th December 20201. Nature Metabolism: Researchers found that the high-density lipoprotein (HDL) scavenger receptor B type 1 (SR-B1) facilitated ACE2-dependent entry of SARS-CoV-2, for the S1 subunit of SARS-2-S bound to cholesterol and possibly to HDL components to enhance viral uptake in vitro. Blockade of the cholesterol-binding site on SARS-2-S1 with a monoclonal antibody or treatment of cultured cells with pharmacological SR-B1 antagonists could inhibit HDL-enhanced SARS-CoV-2 infection. [key info] SR-B1 may be a potential therapeutic target to inhibit SARS-CoV-2 infection.[link]https://www.nature.com/articles/s42255-020-00324-02. Nature Medicine: In a study assessing the effectiveness of control measures against COVID-19 in Wanzhou, China, approximately 67.2% and 32.8% of cases were found symptomatic
………………………………
